Implementation of an anabolic therapy program and follow-up of patients prescribed abaloparatide: real-world results of a pharmacist-led osteoporosis clinic

Loading...
Thumbnail Image
Issue Date
2022
Authors
Kane, Michael P
Arceri, Veronica R ++
Quinn, Hugh B ++
Telese, Mallory ++
Racz, Michael J
Busch, Robert S
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
Utilizing anabolic osteoporosis therapies presents with challenges, including patient acceptance of injections, addressing medication safety concerns, and achieving medication access. We developed a pharmacist-run clinic to ensure the safe and effective use of these therapies. Primary endpoints were comparison of dual energy X-ray absorptiometry (DXA) T-scores and bone mineral density (BMD) values of the total hip, femoral neck, spine, and wrist at baseline, after abaloparatide therapy, and following 1 year of follow-on antiresorptive therapy. The secondary endpoint was the number of documented fractures during the evaluation period. 146 patients were referred for abaloparatide treatment. Ninety-one patients initiated treatment: average age was 66.7 (± 7.7) years, 56% had a history of osteoporotic fracture, baseline T-Scores of the femoral neck and spine were -2.5 (± 0.7), and -2.4 (± 1.3), respectfully. Mean length of therapy was 12 ± 2 months (range 9-18 months). T-scores and BMD significantly improved at all sites except for a significant decrease in T-score at the 1/3 radius. After 1 year of follow-on anti-resorptive treatment, T-scores and BMD significantly increased at the total hip and at the lumbar spine compared to post-abaloparatide, with nonsignificant changes in the femoral neck and 1/3 radius. There was one reported fracture. Eighteen patients (19.8%) discontinued therapy due to adverse drug reactions and there was a 72.5% medication persistence rate. Abaloparatide is effective in increasing BMD and T-scores and in preventing osteoporosis-related fractures. While significant barriers to anabolic osteoporosis treatment remain, involvement of a pharmacist-led clinic may increase medication persistence.
Citation
Kane MP, Arceri VR, Quinn HB, Telese M, Racz MJ, Busch RS. Implementation of an anabolic therapy program and follow-up of patients prescribed abaloparatide: real-world results of a pharmacist-led osteoporosis clinic. Current Trends in Endocrinology. 2022;13:25-35.
Description
Click on the Resource Link to access the article (may not be free).
Grants